Boston Scientific's share price has risen so sharply over the past two years that it has become too expensive for some investors. The company's board of directors has therefore approved a two-for-one stock split, "to provide a trading price range that is accessible to a broader group of investors", it said.
Following the split, the company, which has a market capitalisation of more than $26bn, would have around 823 million outstanding...